相关实验视频
Updated: Jun 15, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.0K
乌帕达西提尼布治疗急性严重性结肠炎:系统性审查
John A Damianos1, Olufemi Osikoya2, Gregory Brennan3
1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Inflammatory bowel diseases
|August 26, 2024
概括
乌帕达西丁 (UPA) 是一种JAK-1抑制剂,在急性严重性结肠炎 (ASUC) 中表现有前途. 这次审查发现UPA在ASUC患者中提供了快速,持续的改善,具有低的胆管切除率和很少的不良事件.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性严重性结肠炎 (ASUC) 带来了重大的临床挑战,往往需要进行切除术.
- 选择性Janus激酶 (JAK) -1 抑制剂Upadacitinib (UPA) 已被批准用于中度至严重的性结肠炎.
- 越来越多的UPA被用于非标签的ASUC管理.
研究的目的:
- 系统地审查有关Upadacitinib (UPA) 在急性严重性结肠炎 (ASUC) 患者的疗效和安全性的现有文献.
主要方法:
- 进行了系统的文献搜索,以确定在ASUC中报告UPA使用的所有研究.
- 来自11项已识别的研究的数据,包括总共55名患者,被汇集用于分析.
主要成果:
- 大多数用UPA治疗的患者表现出快速和持续的临床改善.
- 在90天内切除肠道的发生率为16.3%.
- 在非切除术患者中,80%的患者在随访时实现了无类固醇缓解. 副作用不常见,包括两例静脉血栓栓塞的病例.
结论:
- 在患有急性严重性结肠炎 (ASUC) 的患者中,upadacitinib (UPA) 似乎是一种安全有效的治疗选择.
- UPA为ASUC管理提供了一个有前途的替代方案,可能减少对胆管切除术的需要,并实现缓解.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Inflammatory Bowel Disease I: Ulcerative Colitis
159
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
159
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
Inflammatory Bowel Disease V: Surgical Management
133
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
133

